CJC-1295 With and Without DAC: Peptide Structure, Half-Life, and Experimental GH/IGF-1 Dynamics
A single structural modification — the addition of a maleimidopropionyl group — transforms a peptide with a 30-minute window of activity into one that remains active for nearly eight days. That is the pharmacological story at the heart of CJC-1295 with and without DAC: peptide structure, half-life, and experimental GH/IGF-1 dynamics, and it has significant implications for how researchers design growth hormone secretagogue protocols in vitro and in preclinical models.
Key Takeaways
- CJC-1295 is a 30-amino-acid synthetic analog of growth hormone-releasing hormone (GHRH).
- The Drug Affinity Complex (DAC) modification extends half-life from roughly 30 minutes to approximately 5.8-8.1 days via covalent albumin binding.
- Without DAC (Modified GRF 1-29), the peptide requires more frequent dosing to sustain receptor stimulation.
- A single CJC-1295 with DAC injection can produce a 2- to 10-fold increase in plasma GH lasting up to six days.
- Combining CJC-1295 with ghrelin mimetics such as ipamorelin produces synergistic GH release through complementary pathways.
Peptide Structure: How the DAC Modification Changes Everything
CJC-1295 is built on the first 29 amino acids of endogenous GHRH, with four strategic amino acid substitutions that resist enzymatic degradation. In its unmodified research form — commonly called Modified GRF (1-29) or CJC-1295 without DAC — the peptide retains high receptor affinity but is rapidly cleared from circulation.
The DAC version adds a maleimidopropionyl (MPA) bioconjugate to the peptide's C-terminus. This reactive group forms a covalent thioether bond with the free cysteine-34 residue on circulating serum albumin. Because albumin has a half-life of roughly 19 days and is too large to be filtered by the kidneys, the bound peptide is effectively shielded from proteolytic breakdown.
"The DAC modification does not alter receptor binding affinity — it changes how long the peptide survives long enough to bind."
This distinction matters for assay design. Researchers exploring CJC-1295 and ipamorelin combination protocols must account for whether the DAC form's prolonged presence will create sustained baseline GH stimulation or whether the pulsatile pattern of Modified GRF (1-29) better fits the experimental timeline.
Half-Life Comparison and Experimental Dosing Implications
The pharmacokinetic difference between the two forms is stark:
| Form | Common Name | Approximate Half-Life | Dosing Frequency |
|---|---|---|---|
| CJC-1295 with DAC | DAC-GRF | 5.8 – 8.1 days | Once or twice weekly |
| CJC-1295 without DAC | Modified GRF (1-29) | ~30 minutes | Multiple times daily |
For context, other GHRH analogs fall well below even the without-DAC form: sermorelin has a half-life of 10-12 minutes, and tesa sits at approximately 30 minutes. Researchers can review tesa peptide benefits and pharmacology for a useful comparative baseline.
The without-DAC form is often preferred in protocols that require tight temporal control over GH pulses. Its short window allows researchers to time injections around specific assay windows, mimicking the body's natural ultradian GH rhythm. The DAC form, by contrast, produces a sustained elevation that is better suited to protocols measuring cumulative IGF-1 response over days.
For researchers building multi-peptide stacks, the sermorelin, ipamorelin, and CJC-1295 combination overview provides useful context on how different half-lives interact within the same protocol.
Experimental GH/IGF-1 Dynamics: What the Data Shows
Understanding CJC-1295 with and without DAC: peptide structure, half-life, and experimental GH/IGF-1 dynamics requires examining how each form drives the GH-IGF-1 axis differently.
CJC-1295 with DAC binds GHRH receptors on pituitary somatotroph cells and sustains that stimulation across days. Phase I clinical data shows a single injection can produce:
- A 2- to 10-fold increase in mean plasma GH levels lasting up to six days
- A 1.5- to 3-fold increase in IGF-1 levels persisting for nine to eleven days
Critically, this occurs while preserving pulsatile GH secretion — a key advantage over exogenous GH administration, which suppresses the natural feedback loop. Pulsatility is associated with more physiological receptor sensitivity and reduced tachyphylaxis risk.
CJC-1295 without DAC produces sharp, transient GH spikes that closely mirror endogenous GHRH pulses. This makes it valuable for experiments requiring acute GH measurements or when researchers want to avoid prolonged IGF-1 elevation between assay time points.
Synergistic combinations are a major area of interest. Pairing CJC-1295 with a ghrelin mimetic like ipamorelin activates two distinct receptor pathways — GHRH receptors and ghrelin receptors (GHS-R1a) — simultaneously. The result is GH output greater than either peptide alone. The CJC-1295 ipamorelin assay planning and sourcing checklist is a practical resource for structuring such experiments.
Phase I safety data indicates CJC-1295 is well-tolerated at doses of 30-60 mcg/kg, with mild injection site reactions and occasional headaches as the most commonly noted effects. As of 2026, the peptide remains unapproved for human therapeutic use across most jurisdictions and is classified as a research compound.
For researchers sourcing reference-grade material, the GH axis product line overview and sermorelin ipamorelin CJC-1295 dosage reference guide offer structured starting points. Lyophilized CJC-1295 should be stored at 2-8°C and, once reconstituted, used within 30 days.
Conclusion
The DAC modification is not a minor refinement — it fundamentally redefines how CJC-1295 interacts with the GH-IGF-1 axis. Researchers designing protocols in 2026 should base their form selection on experimental objectives: choose the without-DAC form when temporal precision and pulsatile GH mimicry are priorities, and the DAC form when sustained IGF-1 elevation or infrequent dosing windows are required.
Actionable next steps for researchers:
- Define whether the assay requires acute GH spikes or sustained IGF-1 elevation before selecting a form.
- Consider pairing either form with ipamorelin to leverage synergistic GH secretagogue pathways.
- Verify peptide purity through certificates of analysis before initiating any in vitro or preclinical work.
- Store lyophilized stock at 2-8°C and track reconstitution dates to maintain compound integrity.
- Cross-reference the CJC-1295 product and research reference page for sourcing and specification details.